# OnCo record aall1521 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/aall1521/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "aall1521", "NCT02723994" ;
  schema:name "AALL1521"@en ;
  schema:alternateName "COG AALL1521"@en, "INCB 18424-269"@en ;
  schema:description "AALL1521 is the trial that added the JAK-blocking pill ruxolitinib to chemotherapy for children whose leukaemia looks like Philadelphia-positive disease but is driven by JAK signalling; it has finished treating patients and the survival results are awaited."@en ;
  schema:url <https://onco.cc/trials/aall1521/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02723994> ;
  onco:status "completed" ;
  onco:tag "soc-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/all-ph-like/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/leukaemia/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/ruxolitinib/> ;
  onco:companies <https://onco.cc/companies/incyte/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/> .